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ABSTRACT 
Plasma ACTH and cortisol concentrations are frequently elevated 
in patients in intensive care units (ICU). To examine the functional 
integrity of the hypothalamic-pituitary-adrenal axis during critical 
illness, we evaluated prospectively 53 ICU patients in a general medical 
ICU. Thirty-one patients and 7 normal controls underwent an over- 
night dexamethasone suppression test (3 mg dexamethasone, orally, at 
2300 h). Plasma ACTH and serum co&sol were measured at 0900 h. 
In a separate experiment, 22 patients and 7 control subjects underwent 
a CRH stimulation test [lOO pg human (h) CRH, iv]. ACTH and 
cortisol concentrations were determined from -15 to 120 min. Com- 
pared to normal controls, plasma ACTH and serum cortisol concentra- 
tions were not fully suppressible by dexamethasone [mean ? SEM: 
plasma ACTH, 21 ? 4 us. 3 & 0.5 pg/mL (4.7 & 0.9 us. 0.7 & 0.1 pmol/ 
L); serum cortisol, 13.9 * 1.9 us. 1.5 ? 0.3 pg/dL (390 & 50 us. 40 & 10 
nmol/L); P = O.OOOl], demonstrating an altered glucocorticoid feedback 
in the ICU patients. Patients undergoing hCRH stimulation had clearly 
elevated mean baseline plasma ACTH and serum cortisol concentra- 
tions [ACTH, 78 & 20 pg/mL us. 15 & 3 in controls (17.2 & 4.4 us. 3.4 
? 0.7 pmol/L; P = 0.007); cortisol, 36.8 & 3.4 Ng/dL us. 9.6 ? 1.2 (1020 
& 80 us. 260 + 30 nmol/L: P = O.OOOl)l. Desnite elevated baseline 
glucocorticoid concentratio&, stimulatioi with LCRH resulted in sig- 
nificantly higher peak plasma ACTH concentrations 1.5 min after 
hCRH than in controls 1134 & 31 us. 48 * 9 pg/mL (29.5 * 6.8 us. 10.6 
* 2.0 pmol/L); PC 0.0511 Serum cortisol con&&rations in ICU patients 
were significantly elevated throughout the test period (P = 0.0001) and 
rose to a peak of 43.9 ? 3.5 pg/dL compared to 18.2 & 2.0 pg/dL in 
controls (1210 * 70 us. 500 + 60 nmol/L). We conclude that ICU 
patients have a markedly altered resp&veness of their pituitary 
corticotroph to suppression with dexamethasone and stimulation with 
hCRH. These fin&gs may be explained by altered pituitary glucocor- 
ticoid feedback and/or hypersecretion of peptides with CRH-like activ- 
ity (vasopressin and cytokines) during critical illness. (J Clin Edocri- 
no1 Metab 77: 151-156, 1993) 
I? REVIOUS studies demonstrated that critical illness, such as in patients in intensive care units (ICU), is associated 
with changes in the hypothalamic-pituitary-adrenal (HI’A) 
(l-lo), hypothalamic-pituitary-thyroid (1 l-13), and gonadal 
(14-18) axes; the renin-angiotensin system (19-22); and the 
sympathoadreno-medullary system (6, 23). The response of 
the HPA axis has been shown to be essential for adaptation 
and maintenance of homeostasis during critical illness (24). 
One of the main functions of glucocorticoids seems to be 
modulation and coordination of the stress response by inter- 
acting with other elements of the stress defense (i.e. hor- 
mones, cytokines, lipid mediators of inflammation, and 
bioactive peptides) (24). 
Patients in ICUs have elevated baseline cortisol concentra- 
tions, which are positively correlated with the degree of 
illness as well as with the mortality rate (5, 7). Furthermore, 
patients in ICUs have, compared to controls, higher cortisol 
levels after stimulation with ACTH-(l-24), reflecting adap- 
tation of the adrenal cortex during major stress (5, 10). The 
baseline adrenal steroid secretion shows a shift away from 
adrenal androgen and mineralocorticoid secretion toward 
glucocorticoid secretion (1, 15, 17, 19, 20). 
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The regulation of the HPA axis during critical illness has 
not been studied in detail. We, therefore, studied the re- 
sponse of the HPA axis to suppression with dexamethasone 
and stimulation with human (h) CRH in 53 ICU patients and 
14 normal controls. 
Subjects and Methods 
Patients 
The study was performed during a 6-month period in the medical 
ICU of the Medical Department II, Krankenhaus Merheim, University 
of Koln. Krankenhaus Merheim is an 800-bed tertiary care hospital. The 
ICU is a 9-bed unit, treating approximately 400 patient& mainly 
patients with cardiac or renal disease. The frequency of respirator 
treatment is 50%. The protocol was approved by the Institutional Review 
Board, University of Koln, and all patients or their first degree relatives 
and all normal subjects gave written informed consent. 
Patients were enrolled in this study regardless of the medical condi- 
tion responsible for transfer to the ICI-J. They were studied as soon as 
informed consent could be obtained and as soon as their medical 
condition had been stabilized. Routine medical treatment was given as 
required. Patients with known diseases of the HPA axis, hypoxic brain 
damage, glucocorticoid treatment, gastrointestinal bleeding, fever higher 
than 38.5 C, or emergency procedures, such as surgery, within 48 h 
were excluded from the study. 
In all 53 patients studied, age, sex, main diagnosis, and outcome (in- 
hospital mortality) were determined. The severity of illness was assessed 
on the day the tests were performed using the Therapeutical Intervention 
System Score (TISS-24) (25), which estimates the de8ree of illness by 
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ABSTRACT 
Plasma ACTH and cortisol concentrations are frequently elevated 
in patients in intensive care units (lCU). To examine the functional 
integrity of the hypothalamic-pituitary-adrenal axis during critical 
illness, we evaluated prospectively 53 ICU patients in a general medical 
ICU. Thirty-one patients and 7 normal controls underwent an over-
night dexamethasone suppression test (3 mg dexamethasone, orally, at 
2300 h). Plasma ACTH and serum cortisol were measured at 0900 h. 
In a separate experiment, 22 patients and 7 control 8ubjects underwent 
a CRH stimulation test [100 J.l.g human (h) CRH, iv]. ACTH and 
cortisol concentrations were determined from -15 to 120 min. Com-
pared to normal controls, plasma ACTH and serum cortisol concentra-
tions were not fully suppressible by dexamethasone [mean ± SEM: 
plasma ACTH, 21 ± 4 VS. 3 ± 0.5 pg/mL (4.7 ± 0.9 VS. 0.7 ± 0.1 pmol/ 
L); serum cortisol, 13.9 ± 1.9 VS. 1.5 ± 0.3 J.l.g/dL (390 ± 50 VS. 40 ± 10 
nmol/L); P = 0.0001), demonstrating an altered glucocorticoid feedback 
in the ICU patients. Patients undergoing hCRH stimulation had clearly 
PREVIOUS studies demonstrated that critical illness, such as in patients in intensive care units (lCU), is associated 
with changes in the hypothalamic-pituitary-adrenal (HP A) 
(1-10), hypothalamic-pituitary-thyroid (11-13), and gonadal 
(14-18) axes; the renin-angiotensin system (19-22); and the 
sympathoadreno-medullary system (6, 23). The response of 
the HPA axis has been shown to be essential for adaptation 
and maintenance of homeostasis during critical illness (24). 
One of the main functions of glucocorticoids seems to be 
modulation and coordination of the stress response by inter-
acting with other elements of the stress defense (i.e. hor-
mones, cytokines, lipid media tors of inflammation, and 
bioactive peptides) (24). 
Patients in ICUs have elevated baseline cortisol concentra-
tions, which are positively correlated with the degree of 
illness as well as with the mortality rate (5, 7). Furthermore, 
patients in ICUs have, compared to controls, high er cortisol 
levels after stimulation with ACTH-(1-24), reflecting adap-
tation of the adrenal cortex during major stress (5, 10). The 
baseline adrenal steroid secretion shows a shift away from 
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elevated mean baseline plasma ACTH and serum cortisol concentra-
tions [ACTH, 78 ± 20 pg/mL VS. 15 ± 3 in controls (17.2 ± 4.4 VS. 3.4 
± 0.7 pmol/L; P = 0.007); cortisol, 36.8 ± 3.4 J.l.g/dL VS. 9.6 ± 1.2 (1020 
± 80 VS. 260 ± 30 nmol/L; P = 0.0001)]. Despite elevated baseline 
glucocorticoid concentrations, stimulation with hCRH resulted in sig-
nificantly higher peak plasma ACTH concentrations 15 min after 
hCRH than in controls [134 ± 31 VS. 48 ± 9 pg/mL (29.5 ± 6.8 VS. 10.6 
± 2.0 pmol/L); P < 0.05]. Serum cortisol concentrations in ICU patients 
were significantly elevated throughout the test period (P = 0.0001) and 
rose to a peak of 43.9 ± 3.5 J.l.g/dL compared to 18.2 ± 2.0 J.l.g/dL in 
controls (1210 ± 70 VS. 500 ± 60 nmol/L). We conclude that ICU 
patients have a markedly altered responsiveness of their pituitary 
corticotroph to suppression with dexamethasone and stimulation with 
hCRH. These findings may be explained by altered pituitary glucocor-
ticoid feedback and/or hypersecretion ofpeptides with CRH-like activ-
ity (vasopressin and cytokines) during critical illness. (J Clin Endocri-
nol Metab 77: 151-156, 1993) 
The regulation of the HP A axis during critical illness has 
not been studied in detail. We, therefore, studied the re-
sponse of the HP A axis to suppression with dexamethasone 
and stimulation with human (h) CRH in 53 ICU patients and 
14 normal controls. 
Subjects and Methods 
Patients 
The study was perfor ed during a 6-month period in the medical 
ICU of the Medical Depart ent II, Krankenhaus Merheim, University 
of Koln. Krankenhaus Merheim is an 800-bed tertiary care hospital. The 
lCU is a 9-bed unit, treating approximately 400 patients/yr, mainly 
patients with cardiac or renal disease. The frequency of respirator 
treatment is 50%. The protoeol was approved by the Institutional Review 
Board, University of Koln, and all patients or their first degree relatives 
and aII normal subjects gave written informed consent. 
Patients were enrolled in this study regardless of the medical condi-
ti n responsible for transfer t  he leu. They were studied as soon as 
informed consent could be obtai ed and as soon as their medic l 
condition had been stabilized. Routine medical treatment was given as 
required. Patients with known diseases of the HP A axis, hypoxie brain 
d mage, glucocorticoid treatment, gastrointestinal ble ding, fever higher 
than 38.5 C, o  emergenc  procedures, such as surgery, within 48 h 
were excIuded from the study. 
In aII 53 patients studi d, age, sex, main diagn sis, and outeome (in-
hospital mortaIity) re d te ined. The severity of llness was assessed 
on the day the tests were performed using the Therap utical Intervention 
System Score (TISS-24) (25), which estimates the degree of ilIness by 
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measuring the intensity of treatment given to a particular patient. Blood 
was drawn from either peripheral indwelling catheters or internal jugular 
venous catheters. 
Dexamethasone suppression test 
Thirty-one patients and seven normal subjects underwent an over- 
night dexamethasone suppression test. Clinical data for the study pop- 
ulation are shown in Table 1. At 0900 h on day 1, blood was drawn for 
determination of plasma ACTH and serum cortisol. At 2300 h, all 
subjects received 3 mg dexamethasone, orally (nonintubated patients) 
or via a gastric tube (patients receiving respirator therapy), followed by 
determination of plasma ACTH and serum cortisol the following day at 
0900 h. 
hCRH stimulation test 
In a separate experiment, 22 patients and 7 normal subjects under- 
went a hCRH test at 0900 h in the morning. The characteristics of the 
TABLE 1. Clinical profile of patients who had a dexamethasone 
suppression test 
Controls ICU patients 
Day of test after admission to 
ICU 
Mean TISS 
Respiratory therapy (%) 
Mortality (%) 
Main diagnosis 
Myocardial infarction 
Chronic heart failure 
Cardiogenic shock 
Acute renal failure 
Chronic renal failure 
Liver failure 
ARDS 
5FY2M 
31 
15F/l6M 
58 k 14 672 11 
6.1 & 3.9 (2-16)” 
32 kl0 
39 
41 
5 
2 
2 
F, Female; M, male; TISS, Therapeutical Intervention System Score; 
ARDS, adult respiratory distress syndrome. 
The mean ? SD are shown. 
’ Range is in parentheses. 
TABLE 2. Clinical profile of patients who had a hCRH stimulation 
test 
Controls ICU patients 
5F;M 6F;:M 
61? 11 64kl2 
Day of test after admission to 6.0 & 6.15 (2-25)a 
ICU 
Mean TISS 39 * 10 (15-54) 
Respiratory therapy (%) 82 
Mortality (%) 68 
Main diagnosis 
Myocardial infarction 2 
Chronic heart failure 3 
Pulmonary edema 2 
Cardiogenic shock 4 
Acum renal failure 2 
ARDS 2 
Liver failure 4 
Sepsis/septic shock 3 
F, Female; M, male; TISS, Therapeutical Intervention System Score; 
ARDS, adult respiratory distress syndrome. Shown are the mean * SD. 
a Range is in parentheses. 
Vcd7l.Nol 
subjects are shown in Table 2. After 2 baseline blood samples for 
determination of plasma ACTH and serum cortisol (-15 and 0 mm), 
hCRH (Corticobiss, Bissendorf Peptide, Hannover, Germany) was in- 
jected as a bolus dose of 100 pg, iv. Blood was drawn at 15, 30, 45, 60, 
90, and 120 min. 
Hormone assays 
Plasma ACTH was determined after extraction with Quso GaZ (Phil- 
adelphia Quartz Co.) (26). The lower limit of detection was 3 pg/mL. 
Serum cortisol was measured by a commercial enzyme-linked immu- 
nosorbent assay (Serozym, Serono, Freiburg, Germany). The inter- and 
intraassay coefficients of variation were below 9% and 6% for both 
assays, respectively. All samples from a patient were measured in the 
same assay. 
Data analysis 
The total and net integrated ACTH and cortisol responses to hCRH 
were calculated by the trapezoid method and expressed as the area 
under the concentration-time curve (AUC) from O-120 min. All values 
are expressed as the mean ? SEM, if not otherwise stated. Statistical 
significance of the differences was assessed using the Mann-Whitney lJ 
test for unpaired data. Correlations were examined with linear regression 
analysis and expressed as the Pearson’s correlation coefficient. P 5 0.05 
was considered statistically significant. 
Results 
Dexamethasone suppression test 
Compared to normal subjects, baseline plasma ACTH 
concentrations at 0900 h were slightly, but not significantly, 
higher in KU patients, whereas baseline cortisol concentra- 
tions were clearly elevated (Fig. 1). After dexamethasone 
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FIG. 1. Mean responses of plasma ACTH and serum cortisol to 
suppression with dexamethasone in 7 normal controls and 31 ICU 
patients. To convert ACTH concentrations to picomoles per L, multiply 
by 0.2202; to convert cortisol concentrations to nanomoles per L, 
multiply by 27.6. 
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analysis and expressed as the Pearson's correlation coefficient. P:s 0.05 
was considered statistically significant. 
Results 
Dexamethasone suppression test 
Compared to normal subjects, baseline plasma ACTH 
concentrations at 0900 h were slightly, but not significantly, 
higher in lCU patients, whereas baseline cortisol concentra-
tions were dearly elevated (Fig. 1). After dexamethasone 
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FIG. 1. Mean responses of plasma ACTH and serum cortisol to 
suppression with dexamethasone in 7 normal controls and 31 ICU 
patients. To convert ACTH concentrations to picomoles per L, multiply 
by 0.2202; to convert cortisol concentrations to nanomoles per L, 
multiply by 27.6. 
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administration, plasma ACTH as well as cortisol concentra- 
tions were suppressed in normal subjects. In contrast, ICU 
patients showed significantly elevated mean ACTH (P = 
0.0001) and cortisol concentrations (P = O.OOOl), demonstrat- 
ing an altered negative feedback regulation of glucocorticoids 
during critical illness. 
ACTH and cortisol concentrations in ICU patients were 
significantly correlated with the in-hospital mortality rate 
(Table 3). Patients who later died during the hospital stay 
had higher postdexamethasone ACTH concentrations (P = 
0.02) and cortisol concentrations (P = 0.04) than patients 
who were discharged from the hospital. 
hCRH stimulation test 
Baseline plasma ACTH concentrations showed a great 
variability in ICU patients, but were significantly higher than 
those in the controls (Fig. 2; P = 0.007). In addition, baseline 
cortisol concentrations were significantly elevated (P = 
0.0001). The individual ACTH response to hCRH in ICU 
patients was characterized by an ACTH increase ranging 
from 7-450% of the baseline value and was not dependent 
on the baseline cortisol concentrations (r = 0.05; P = 0.8). 
Mean ACTH concentrations rose to a peak of 134 & 31 pg/ 
mL (29.5 k 6.9 pmol/L) 15 min after the injection of hCRH 
compared with 48 * 9 pg/mL (10.6 & 2.0 pmol/L) in control 
subjects (P = 0.046; Fig. 2). The total AUC and the maximum 
ACTH concentrations (Fig. 3), but not the net AUC, were 
also significantly higher than those in controls. 
Mean cortisol concentrations in ICU patients were signifi- 
cantly elevated throughout the test period (P < O.OOOl), and 
the total AUC for cortisol was clearly higher than that in the 
controls (P = 0.0001). The cortisol increase in ICU patients 
(P = 0.8) as well as the net AUC (P = 0.4) were similar in 
ICU patients and controls. 
Baseline ACTH concentrations were significantly higher 
in patients who later died during the hospital stay than those 
in patients who survived and were discharged from the 
hospital [95 & 28 us. 42 & 16 pg/mL (20.9 5 6.1 ZK 9.2 * 
3.5 pmol/L); P = 0.041. In addition, the total AUC of non- 
survivors was significantly higher than that in control sub- 
jects (P = 0.04; Table 3), whereas survivors did not have 
significantly higher total AUC than controls. Baseline serum 
cortisol concentrations and the total time-integrated cortisol 
secretion did not differ between patients who later died and 
patients who survived. 
Discussion 
The response of the HI’A axis has been shown to be an 
integral part of the adaptation to emotional and physical 
stress. Critical illness, such as in ICU patients, is one of the 
most powerful activators of the HPA axis. ACTH and cortisol 
concentrations in sepsis (8), after extensive bums (15) or 
brain trauma (9), or in shock are elevated and may reach 
extraordinarily high levels depending on the degree of illness. 
Whereas it is well established that ICU patients have bio- 
chemical evidence of hypercortisolism, little is known of the 
functional integrity of the HI’A axis during critical illness. 
The data from our dynamic evaluation show that the re- 
sponse of the HI’A axis to suppression by dexamethasone 
and stimulation by hCRH is profoundly altered in ICU 
patients. Treatment of ICU patients with dexamethasone at 
a dose that easily suppresses ACTH and cortisol secretion in 
normal subjects was minimally effective in our patients. In 
addition, stimulation with hCRH resulted in an augmented 
ACTH response in spite of very high baseline cortisol con- 
centrations, which probably would have been sufficient to 
blunt or abolish the hCRH-induced ACTH surge in normal 
subjects. Taken together, the observed abnormalities in the 
HI’A axis of ICU patients are unique and have not been 
reported in any of the well characterized biochemically hy- 
percortisolemic states, such as major depression (27), preg- 
nancy (28), and renal insufficiency (29). The comparison to 
the findings in major depression is particularly noteworthy, 
since chronic emotional stress associated with depression 
may be seen as a counterpart to the chronic physical stress 
of ICU patients. Similar to ICU patients, patients with depres- 
sion are also hypercortisolemic and show a blunted cortisol 
response to suppression with dexamethasone (27). However, 
the response to exogenous stimulation with CRH in de- 
pressed patients is characterized by a blunted ACTH re- 
sponse, presumably because of the negative feedback of 
elevated endogenous glucocorticoids on ACTH release. In 
contrast, in ICU patients, the negative feedback of endoge- 
nous glucocorticoids on pituitary ACTH secretion is clearly 
altered, and stimulation with hCRH results in high plasma 
ACTH concentrations in spite of elevated baseline cortisol 
TABLE 3. Influence of subsequent mortality on ACTH and cortisol responses to dexamethasone and CRH 
Dexamethasone suppression test hCRH stimulation test 
Basal ACTH [pg/mL ACTH after 3 mg dex Basal cortisol [pg/dL Cortisol after 3 mg dex 
Total AUC Total AUC 
~PnwL~l hx/mL (p~oW)l klmol/L)l [&dL (nmol/L)l 
ACTH (pg/mL corns01 (pg/ 
mitt) dL.min) 
Controls 24 k 6 (5.3 k 1.2) 3 k 0.5 (0.7 2 0.1) 12.1 k 1.2 (330 * 30) 1.5 * 0.3 (40 iz 10) 4,390 * 570 1,881 k 213 
Patients 
Survivors 26 k 10 (5.7 k 2.2) 18 k 5 (3.9 zk l.l)a 19.5 k 1.9 (330 zk 50)’ 11.4 k 2.3 (310 2 60)’ 6.740 k 2,110 4,586 k 455’ 
Nonsurvivors 41 k 15 (9.0 k 3.3) 28 k 7 (6.2 k l.5)a,b 37.0 k 6.9 (1020 k 220Pc 17.3 k 2.9 (480 k 8OP 14,470 * 3,980 5,166 + 567’ 
0 P < 0.02 controls. us. 
* P < 0.02 US. survivors. 
’ P < 0.05 us. survivors. 
d P < 0.05 us. controls. 
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0.0001). The individual ACTH response to hCRH in ICU 
patients was characterized by an ACTH increase ranging 
from 7-450% of the baseline value and was not dependent 
on the baseline cortisol concentrations (r = 0.05; P = 0.8). 
Mean ACTH concentrations rose to a peak of 134 ± 31 pg/ 
mL (29.5 ± 6.9 pmol/L) 15 min after the injection of hCRH 
compared with 48 ± 9 pg/mL (10.6 ± 2.0 pmol/L) in control 
subjects (P = 0.046; Fig. 2). The total AUC and the maximum 
ACTH concentrations (Fig. 3), but not the net AUe, were 
also significantly higher than those in controls. 
Mean cortisol concentrations in ICU patients were signifi-
cantly elevated throughout the test period (P < 0.0001), and 
the total AUC for cortisol was clearly higher than that in the 
controls (P = 0.0001). The cortisol increase in ICU patients 
(P = 0.8) as weIl as the net AUC (P 0.4) were similar in 
ICU patients and controls. 
Baseline ACTH concentrations were significantly higher 
in patients who later died during the hospital stay than those 
in patients who survived and were discharged from the 
hospital [95 ± 28 VS. 42 ± 16 pg/mL (20.9 ± 6.1 VS. 9.2 ± 
3.5 pmol/L); P = 0.04]. In addition, the total AUC of non-
survivors was significantly higher than that in control sub-
jects (P = 0.04; Table 3), whereas survivors did not have 
significantly higher total AUC than controls. Baseline serum 
cortisol concentrations and the total time-integrated cortisol 
secretion id ot iffer etween atients ho later ied a  
tients ho r ived. 
iscussion 
The response of the P A axis has been sho n to be an 
integral part of the adaptation to e otional and physical 
stress. Critical illness, such as in ICU patients, is one of the 
ost po erful activators of the P  axis. TH and cortisol 
concentrations in sepsis (8), after extensive bums (15) or 
brain trauma (9), or in shock are elevated and may reach 
extraordinarily high levels depending on the degree of illness. 
Whereas it is weIl established that ICU patients have bio-
chemical evidence of hypercortisolism, little is known of the 
functional integrity of the HP A axis during critical illness. 
The da ta from our dynamic evaluation show that the re-
sponse of the HP A axis to suppression by dexamethasone 
and stimulation by hCRH is profoundly altered in ICU 
patients. Treatment of ICU patients with dexamethasone at 
a dose that easily suppresses ACTH and cortisol secretion in 
normal subjects was minimally effective in our patients. In 
addition, stimulation with hCRH resulted in an augmented 
ACTH response in spite of very high baseline cortisol con-
centrations, which probably would have been sufficient to 
blunt or abolish the hCRH-induced ACTH surge in normal 
subjects. Taken together, the observed abnormalities in the 
HP A axis of ICU patients are unique and have not been 
reported in any of the well characterized biochemically hy-
percortisolemic states, such as major depression (27), preg-
nancy (28), and renal insufficiency (29). The comparison to 
the findings in major depression is particularly noteworthy, 
since chronic emotional stress associated with depression 
may be seen as a counterpart to the chronic physical stress 
of ICU patients. Similar to ICU patients, patients with depres-
sion are also hypercortisolemic and show a blunted cortisol 
response to suppression with dexamethasone (27). However, 
the response to exogenous stimulation with CRH in de-
pressed patients is characterized by a blunted ACTH re-
sponse, presumably because of the negative feedback of 
elevated endogenous glucocorticoids on ACTH release. In 
contrast, in ICU patients, the negative feedback of endoge-
nous glucocorticoids on pituitary ACTH secretion is clearly 
altered, and stimulation with hCRH results in high plasma 
ACTH concentrations in spite of elevated baseline cortisol 
TABLE 3. Influence of subsequent mortality on ACTH and cortisol responses to dexamethasone and CRH 
Basal ACTH [pg/mL 
(pmol/L)] 
Controls 24 ± 6 (5.3 ± 1.2) 
Patients 
Survi rs 26 ± 0 (5.7 ± 2.2) 
Nonsurvivors 41 ± 15 (9.0 ± 3.3) 
o    vs. contr l
b   2 v . ivors. 
c . vs. survivors. 
d P < 0.05 vs. controls. 
Dexamethasone suppression test 
ACTH after 3 mg dex Basal cortisol [/lg/dL 
[pg/mL (pmol/L)] (nmol/L)] 
3 ± 0.5 (0.7 ± 0.1) 12.1 ± 1.2 (330 ± 30) 
1  ± 5 (3.9 ± 1.1)0 19.5 ± 1.9 (330 ± 50)0 
28 ± 7 (6.2 ± 1.5)a,b 37.0 ± 6.9 (1020 ± 220)0" 
hCRH stimulation test 
Cortisol after 3 mg dex otal AUC Total AUC ACTH (pg/mL. cortisol (/lg/ [/lg/dL (nmol/L)] 
min) dL.min) 
1.5 ± 0.3 (40 ± 10) 4,390 ± 570 1,881 ± 213 
11.4 ± 2.3 (310 ± 60)0 6.740 ± 2,110 4,586 ± 4550 
17.3 ± 2.9 (480 ± 80)0,e 14,470 ± 3,980' 5,166 ± 5670 
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FIG. 2. Mean responses of plasma 
ACTH and serum cortisol to stimulation 
with hCRH in 7 normal controls (CON., 
CO.) and 22 ICU patients (PAT., PA.). 
The m.se& show the total (TOT) and net 
integrated (NET) hormone responses, 
expressed as the secretory AUC. To con- 
vert ACTH concentrations to picomoles 
per L, multiply by 0.2202; to convert 
cortisol concentrations to nanomoles per 
L, multiply by 27.6. 
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levels. This observation may be explained in several ways. 
The responsiveness of the pituitary corticotroph to exoge- 
nous CRH in the presence of high endogenous glucocorticoid 
levels may be due to diminished sensitivity of the cortico- 
troph to glucocorticoids in critically ill patients. Pituitary 
resistance to glucocorticoids in ICU patients could be caused 
by abnormalities in the transduction of the effects of gluco- 
corticoids. Recently, a subgroup of acquired immunodefi- 
ciency syndrome patients was identified who had cortisol 
resistance characterized by elevated ACTH and cortisol con- 
centrations and a diminished glucocorticoid receptor affinity 
in circulating mononuclear cells (30). Similar alterations in 
glucocorticoid receptor function may be partially responsible 
for changes in the HF’A axis of ICU patients and could result 
in an augmented ACTH response to CRH. 
Alternatively, the ACTH hypersecretion in ICU patients 
may also be explained by elevated levels of peptides and 
hormones with CRH-releasing properties, which exaggerate 
the effects of endogenous and exogenous CRH on pituitary 
ACTH release. Vasopressin is a stress hormone frequently 
0 30 60 90 I20 150 
TIME (MIN.1 
elevated during major surgery and severe illness (31). It 
exhibits a synergistic effect on ACTH release when given in 
combination with CRH (32-34). Its action makes it a likely 
candidate for the observed activation of the HPA axis during 
critical illness. Other peptides involved in CRH and ACTH 
release which may be elevated during major stress include 
angiotensin-II (35) and neuropeptide-Y (36). 
Another explanation for activation of the HPA axis during 
critical illness is the interaction between the immune and 
neuroendocrine systems. The inflammatory cytokines inter- 
leukin-lp, interleukin-6, and tumor necrosis factor-a are 
frequently elevated in ICU patients (37, 38) and have prog- 
nostic significance. Endotoxin administration to normal vol- 
unteers is associated with a probably cytokine-mediated 
ACTH and cortisol release (39). In addition, interleukin-l/3, 
interleukin-6, and tumor necrosis factor-a have CRH- and/ 
or ACTH-releasing properties in vim and in z&o (40-45). 
These potent peptides may, therefore, stimulate ACTH and 
cortisol secretion in critical illness. 
Critical illness is often associated with conditions such as 
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levels. This observation may be explained in several ways. 
The responsiveness of the pituitary cortieotroph to exoge-
nous CRH in the presence of high endogenous glucocortieoid 
levels may be due to diminished sensitivity of the cortieo-
troph to glucocortieoids in critieally il1 patients. Pituitary 
resistance to glucocortieoids in ICU patients could be caused 
by abnormalities in the transduction of the effects of gluco-
corticoids. Recently, a subgroup of acquired immunodefi-
ciency syndrome patients was identified who had cortisol 
resistance characterized by elevated ACTH and cortisol con-
centrations and a diminished glucocortieoid receptor affinity 
in circulating mononuclear cells (30). Similar alterations in 
glucocorticoid receptor function may be partially responsible 
for changes in the HPA axis of ICU patients and could result 
in an augmented ACTH response to CRH. 
Altematively, the ACTH hypersecretion in ICU patients 
mayaiso be explained by elevated levels of peptides and 
hormones with CRH-releasing properties, which exaggerate 
the effects of endogenous and exogenous CRH on pituitary 
ACTH release. Vasopressin is a stress hormone frequently 
o 30 60 90 120 150 
TIME (MIN.) 
elevated during major surgery and severe illness (31). It 
exhibits a synergistic effect on ACTH release when given in 
combination with CRH (32-34). Its action makes it a likely 
candidate for the observed activation of the HPA axis during 
critical illness. Other peptides involved in CRH and ACTH 
release which may be elevated during major stress include 
angiotensin-II (35) and neuropeptide-Y (36). 
Another explanation for activation of the HP A axis during 
critical illness is the interaction between the immune and 
neuroendocrine systems. The inflammatory cytokines inter-
leukin-1ß, interleukin-6, and tumor necrosis factor-a are 
frequently elevated in ICU patients (37, 38) and have prog-
nostie significance. Endotoxin administration to normal vol-
unteers is associated with a probably cytokine-mediated 
ACTH and cortisol release (39). In addition, interleukin-1ß, 
interleukin-6, and tumor necrosis factor-a have CRH- and/ 
or ACTH-releasing properties in vivo and in vitro (40-45). 
These potent peptides may, therefore, stimulate ACTH and 
cortisol secretion in critical illness. 
Critical illness is often associated with conditions such as 
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FIG. 3. Maximum plasma ACTH and serum cortisol concentrations 
after stimulation with hCRH in 7 normal controls and 22 ICU patients. 
The mean ACTH (P = 0.05) and cortisol concentrations (P = 0.0002) 
were significantly different in the 2 groups. To convert ACTH concen- 
trations to picomoles per L, multiply by 0.2202; to convert cortisol 
concentrations to nanomoles per L, multiply by 27.6. 
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